London, 16th June 2016 – Alacrita, the life sciences consulting firm, today announced that it has appointed Keith Bragman MD FRCP FRCPath FFPM as a Partner in its London office.
Dr Bragman will join the firm’s drug development practice and the move helps consolidate Alacrita’s position as a leading provider of clinical development advice to life science companies developing novel therapeutic agents. Dr Bragman is the immediate Past President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and has advised organisations such as the Science & Technology Committee of the House of Commons, DFID, the Bill and Melinda Gates Foundation, Imperial College London, and UNITAID. Previous appointments include Director and Head of Global Development at UCB, Vice President of Biotechnology and the Anti-Infectives Strategic Business Unit at Quintiles, European Head of Clinical Virology at Hoffmann-La Roche and Director and European Head of Clinical Oncology at BMS.
Dr Bragman joins a growing team of specialists at Alacrita who have distinguished track records of developing novel therapeutic agents. Alacrita is supported by a team of Associates across Europe and the U.S., all of whom are carefully selected for their deep life science industry experience and expertise. The firm supports clients with product development, transaction support and transatlantic expansion advice.
Keith Bragman said “I am delighted to be joining the Alacrita team, which has an impressive track record of advising client organizations in the life sciences. The pace of innovation in our industry is accelerating while the complexity of clinical development is increasing. I look forward to engaging with our clients on their drug development and commercialization efforts.”
Anthony Walker, Managing Partner at Alacrita, said: “We are delighted to welcome Keith to our product development practice as we build a best-in-class consulting practice to help companies develop better therapeutics. Keith is an experienced executive with deep and broad knowledge of the drug development process and a sound understanding of the challenges faced by senior management. He joins a high calibre team of seasoned consultants and underlines our commitment to providing exceptionally high quality advice to the industry.”